Before We Start
Selective activation, not selective entry
Acyclovir doesn't avoid healthy cells — it goes everywhere. What makes it safe is that it stays inactive everywhere except inside cells that happen to contain an enzyme only herpesviruses produce.
💡 Memory Trick
Acyclovir: requires viral thymidine kinase to activate — selective toxicity. Herpes/VZV only. The drug is harmless cargo until a virus-specific enzyme switches it on.
The Key Points
The activation trick, the mechanism once active, uses, and resistance
TK
The activation trick — viral thymidine kinase
Acyclovir actually enters every cell in the body, infected or not. But it only becomes active in cells that contain viral thymidine kinase (TK) — an enzyme that only herpesviruses produce. Uninfected human cells simply don't have the enzyme needed to activate the drug, which is the entire basis of acyclovir's selective toxicity.
🦠 Acyclovir reaching a healthy, uninfected cell does nothing at all, since that cell has no viral thymidine kinase available to switch the drug on — the drug is present but completely inert there.
Mech
Mechanism once activated — halting viral DNA polymerase
Once phosphorylated by viral thymidine kinase, the activated form of acyclovir inhibits viral DNA polymerase, halting viral replication specifically within infected cells.
🦠 Only cells where the drug has actually been activated by viral TK go on to have their viral DNA polymerase blocked — the activation step is what determines where the drug's effect actually lands.
Use
Clinical uses — herpesviruses specifically
Acyclovir treats HSV-1 and HSV-2 (cold sores, genital herpes), VZV (chickenpox, shingles), and, given intravenously, HSV encephalitis — a serious, potentially fatal infection.
🦠 IV acyclovir is used for HSV encephalitis specifically because of the severity and mortality risk of that infection, whereas milder HSV/VZV presentations are typically managed with oral formulations.
Val
Valacyclovir and resistance
Valacyclovir is simply an oral prodrug of acyclovir, offering better bioavailability and less frequent dosing. Resistance can develop through mutations in viral thymidine kinase, most often seen in immunocompromised patients — since without functional TK, the drug can no longer be activated inside the infected cell at all.
🦠 An immunocompromised patient with recurrent herpes outbreaks stops responding to acyclovir over time — a thymidine kinase mutation has likely developed, meaning the virus itself has become resistant to the drug's core activation mechanism.
🏥 Applied Scenario
A patient with HSV encephalitis is started on intravenous acyclovir.
Step 1
Explain why widespread toxicity doesn't occur: Why doesn't this drug cause the same widespread toxicity that many antivirals do, given that it reaches every cell in the body? Because acyclovir only becomes active in cells containing viral thymidine kinase — an enzyme that only herpes-infected cells possess. Healthy, uninfected cells throughout the body simply can't activate the drug, so it does no harm there.
Step 2
Consider what happens if resistance develops: If a patient's herpes infection develops resistance over time, particularly if immunocompromised, the mechanism is usually a mutation in the viral thymidine kinase itself — since the drug depends entirely on that enzyme for activation, a mutated or absent TK renders acyclovir ineffective regardless of dose.
Step 3
Recognize why this mechanism is pedagogically notable: This selective-activation mechanism — rather than a selective-target mechanism — is what makes acyclovir a particularly elegant example of selective toxicity in pharmacology, and it's exactly the kind of underlying reasoning exams want you to understand, not just memorize.
Step 4
Conclusion: Selective toxicity doesn't always mean a drug only reaches the pathogen — sometimes, as with acyclovir, it means the drug reaches everywhere but only gets turned on where it matters.
📌 Exam Application
Exams test the mechanism of selective toxicity (acyclovir requires viral thymidine kinase for activation, an enzyme unique to herpes-infected cells), what the activated drug does once phosphorylated (inhibits viral DNA polymerase), the difference between acyclovir and valacyclovir (the latter is simply an oral prodrug), and the resistance mechanism (TK mutation, especially in immunocompromised patients).
⚠️ The Trap — Assuming Acyclovir Works Broadly Against Many Viruses
The most common trap is assuming acyclovir works broadly against many types of viruses the way a general antiviral might. It specifically and only works against viruses that produce thymidine kinase — herpesviruses (HSV, VZV) — and has no meaningful activity against viruses lacking this enzyme, regardless of how the drug is dosed or administered.
✓ Quick Self-Test
Answer before checking:
1. Why does acyclovir only affect herpes-infected cells and not healthy cells, even though it enters all cells?
2. What does activated acyclovir do once inside an infected cell?
3. What is valacyclovir, and how does it differ from acyclovir?
4. What is the most common mechanism of acyclovir resistance, and in which patients is it most often seen?
5. What conditions does acyclovir treat?
Answers:
1. Because it only becomes active once phosphorylated by viral thymidine kinase, an enzyme that only herpes-infected cells produce; uninfected cells can't activate the drug.
2. It inhibits viral DNA polymerase, halting viral replication.
3. It's an oral prodrug of acyclovir, offering better bioavailability and less frequent dosing — otherwise the same active drug.
4. Mutation in viral thymidine kinase, most often seen in immunocompromised patients.
5. HSV-1 and HSV-2 (cold sores, genital herpes), VZV (chickenpox, shingles), and HSV encephalitis (IV).